A 33-page internal document. Two years of foot-dragging before it saw daylight. And conclusions that, frankly, read less like a scientific review and more like a brief written by someone who had already decided how the story ends.

That's the short version of the Drug Enforcement Administration's report on ayahuasca — a paper titled Ayahuasca: Risks to Public Health and Safety, dated July 2020, finally pried loose through a Freedom of Information Act request by the Chacruna Institute and the Church of the Eagle and the Condor. If you're a reader who's been quietly considering an ayahuasca retreat, weighing whether plant medicine might help with depression, addiction, or some stuck place in your life, this document matters. Not because it's accurate. Because it shapes the legal and cultural weather around the medicine you're researching.

Let's walk through what the report actually says, where it bends the evidence, and what the broader scientific record looks like when you read it without an agenda.

Why a Buried DEA Report Still Shapes the Ayahuasca Conversation

Ayahuasca occupies a strange legal space in the United States. The Supreme Court ruled in 2006 that the União do Vegetal — one of the syncretic Brazilian churches that uses the brew as a sacrament — has a constitutional right to do so under religious freedom protections. Santo Daime won similar protections shortly after. But for newer congregations like the Church of the Eagle and the Condor, getting recognition is a grind, and federal documents like this one are quietly cited to justify keeping the brakes on.

So when an agency with enforcement power produces a paper that looks scientific — footnotes, citations, clinical language — it carries weight far beyond its actual rigor. That's what makes the contents worth picking apart.

The Risk Numbers, in Context

Here's where the report gets specific. It cites the American Association of Poison Control Centers, which logged 538 ayahuasca-related emergency calls between 2005 and 2015. Of those, 150 involved ICU or semi-ICU stays. There were 28 intubations, seven respiratory arrests, and four cardiac arrests. A separate request covering 2012 to 2017 turned up 341 ayahuasca-linked cases and 122 involving DMT specifically.

Those numbers sound scary in isolation. Read them again with the timeframe attached. We're talking about a decade. Across an entire country. During years when ayahuasca use was expanding rapidly through both religious and underground channels. And — this is the part the DEA buries on the same page — the agency itself acknowledges that 43% of the cases involved ayahuasca taken alongside other substances. Which means there's no clean way to say the medicine caused the harm.

For comparison, the same poison control system fields roughly two million calls every year for everything from accidental Tylenol overdoses to kids eating houseplants. The ayahuasca slice is, statistically, a rounding error. None of which is to say risk doesn't exist — it does, and we'll get to it — but the framing matters.

Where the Report Plays Fast and Loose

The pattern, once you see it, repeats throughout the document. Cite a study. Acknowledge its findings are modest or inconclusive. Then pivot to a hypothetical worst-case scenario and treat it as the takeaway.

A few examples:

• The lethal dose argument. The report cites pharmacological research showing you'd need to drink somewhere between 15 and 50 times the ceremonial dose of ayahuasca to reach LD50 — the dose that kills half the test animals in toxicology studies. Rather than concluding that ceremonial doses are therefore well below the danger threshold, the DEA notes that brew strength varies, and uses that variability to argue that ritual or recreational use could approach lethal levels. Could. The word does a lot of work in this document.
• The dependence claim. Pharmacology literature is clear that DMT — the primary visionary compound in ayahuasca — does not produce tolerance. You don't need bigger doses over time to feel the same effects, which is one of the textbook markers of addiction potential. The DEA acknowledges this, then speculates that long-term ayahuasca use might cause structural brain changes that could, hypothetically, lead to dependence. No evidence is offered. Just the possibility.
• The psychosis section. The report cites four clinical cases of psychotic episodes linked to ayahuasca. Four. It then notes the occurrence is low — before warning that the consequences could still be severe. True of almost any psychoactive substance, including caffeine in extreme cases.
• The mortality discussion. One of the deaths the report opens with involved a young man who drank what he thought was ayahuasca but turned out to contain a heavy dose of 5-MeO-DMT — a related but distinct compound found in certain frog secretions and lab synthesis, not in traditional brew. Including that case in an ayahuasca risk assessment is, to put it gently, sloppy.

What's striking isn't that the report mentions risks. Risks deserve mention. What's striking is the asymmetry. When the data points toward danger, the language is confident. When it points toward benefit, suddenly the studies are too small, the controls too weak, the population too narrow.

What's Missing From the Bibliography

Here's the omission that should bother anyone who cares about honest science. The report is dated July 2020. A landmark study had been published the year before: the first placebo-controlled clinical trial of ayahuasca for treatment-resistant depression, run by Dráulio de Araújo's team at the Federal University of Rio Grande do Norte. Twenty-nine participants. Real methodology. Promising results.

It's not in the DEA bibliography. Not cited, not addressed, not refuted. Just absent. You can draw your own conclusions about why a federal review of ayahuasca's therapeutic potential, written in 2020, would simply leave out the most rigorous clinical trial on the subject.

The broader academic literature tells a different story than the one the DEA constructs. Recent reviews — including a thorough survey by Brazilian researchers Maia, Daldegan-Bueno, Wießner, de Araújo, and Tófoli in European Neuropsychopharmacology — conclude that the strongest evidence for ayahuasca's therapeutic effects lies in two areas: depression and substance use disorders. Which, if you're researching plant medicine because you're struggling with one of those things, is exactly the conversation you're trying to have.

What the Honest Risk Picture Actually Looks Like

A review published in Human Psychopharmacology by James, Keppler, Robertshaw, and Sessa covers much of the same source material as the DEA report — but reads like it was written by people who actually wanted to understand the medicine rather than build a case against it.

Their conclusions are worth quoting because they sound like the kind of thing a thoughtful retreat facilitator would tell you: screening matters. Preparation matters. People with personal or family histories of psychosis carry real elevated risk and should probably not drink ayahuasca. But for healthy individuals using the brew in a structured ceremonial context, the data simply does not support the alarmist framing. Incidence of psychosis in ayahuasca drinkers is reported at under 0.1% of consumers. The União do Vegetal alone has roughly 22,000 members who drink ceremonially every two weeks, year after year, with very rare serious adverse events.

That's the lived data. Decades of it. Across continents.

What This Means If You're Considering a Retreat

None of this means ayahuasca is harmless or right for everyone. The honest version is more nuanced:

1. Screening is real medicine. A reputable retreat will ask hard questions about your psychiatric history, family mental health background, current medications (SSRIs and certain other meds interact dangerously with the brew's MAOI components), and cardiovascular health. If a retreat doesn't ask, that's a flag.
2. Context is most of the safety profile. The cases that ended badly almost always involved either underlying health conditions, mixing with other drugs, or unstructured settings without experienced facilitators. The same brew, in a ceremonial container with screening and integration support, has a profoundly different risk profile.
3. Integration is not optional. The ceremony is maybe 30% of the work. What you do in the weeks and months afterward — therapy, journaling, somatic practice, community — is where the lasting shifts happen or don't.
4. The legal landscape varies. In the US, ayahuasca remains a Schedule I substance outside specific religious exemptions. Many people travel to Peru, Costa Rica, Brazil, or other countries where ceremonial use exists in clearer legal space. That's worth understanding before you book anything.

The DEA's report will probably keep circulating in policy circles for years. Documents like that have long half-lives. But you don't have to take its framing at face value. The science is out there, the ceremonial tradition is older than most modern nations, and the safety record — when the medicine is used the way it has been used for centuries — is considerably better than the prohibitionist paper would have you believe.

If, after sitting with all of this, you want to take the next step and actually look at structured options, curated ayahuasca retreats can be browsed on our marketplace here. Read carefully, ask the screening questions back, and trust the slow process of choosing well.